No Data
No Data
HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 price target.
Optimistic Outlook for Syros Pharmaceuticals With Promising Clinical Trials and Regulatory Advancements
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
Earnings Call Summary | Syros Pharmaceuticals(SYRS.US) Q1 2024 Earnings Conference
The following is a summary of the Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript:Financial Performance:Syros reported no revenue in Q1 2024 due to the termination of its collabora
Buy Rating Affirmed for Syros Pharmaceuticals Amidst Clinical Advancements and Market Readiness
Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript